Exelixis (NASDAQ:EXEL) EVP Sells $2,187,757.85 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 43,451 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president directly owned 594,741 shares in the company, valued at $29,945,209.35. This represents a 6.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Exelixis Stock Performance

Shares of EXEL traded up $1.42 during mid-day trading on Thursday, hitting $51.45. 3,572,185 shares of the company’s stock were exchanged, compared to its average volume of 2,731,498. The company has a market cap of $12.93 billion, a price-to-earnings ratio of 17.09, a P/E/G ratio of 1.06 and a beta of 0.38. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $52.96. The stock’s 50-day moving average is $45.64 and its 200-day moving average is $44.10.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.55 earnings per share. As a group, equities research analysts anticipate that Exelixis, Inc. will post 3.15 EPS for the current year.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, reinforcing expectations that the company can continue delivering solid profitability.
• Positive Sentiment: Exelixis is set to participate in upcoming June investor conferences, which can help keep attention on the stock and provide new updates on pipeline and commercial progress. Article Title
• Positive Sentiment: A recent article argued that profitable, cash-generative biotech names like Exelixis may benefit as investors rotate away from expensive growth stocks and toward defensive healthcare ideas. Article Title
• Positive Sentiment: At the company’s annual meeting, investors backed the board, equity plan, and executive pay, signaling governance support and reducing uncertainty. Article Title
• Neutral Sentiment: Exelixis presented at Bernstein’s Strategic Decisions Conference, which keeps the company visible to institutional investors but did not include any major new operating update. Article Title
• Neutral Sentiment: A short-interest report showed essentially no short interest in Exelixis, suggesting limited bearish positioning but not a meaningful catalyst on its own.
• Negative Sentiment: EVP Dana Aftab sold 43,451 shares at an average price of $50.35, a disclosed insider sale that can weigh on sentiment even though the executive still holds a large position. Article Title

Institutional Trading of Exelixis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Exelixis by 81.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares in the last quarter. Focus Partners Wealth raised its holdings in Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares in the last quarter. Finally, Sivia Capital Partners LLC raised its holdings in Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EXEL. Wells Fargo & Company raised their target price on shares of Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. HC Wainwright raised their target price on shares of Exelixis from $54.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, May 7th. TD Cowen raised their target price on shares of Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Truist Financial raised shares of Exelixis to a “strong-buy” rating in a report on Monday, April 27th. Finally, Royal Bank Of Canada reduced their target price on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $47.35.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.